1952 — Everest Medicines Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$7.99bn
- HK$6.03bn
- CNY125.93m
- 11
- 10
- 62
- 13
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -215 | -5,658 | -1,009 | -247 | -844 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 54 | 5,088 | 184 | -951 | 66.5 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 61.9 | 77.9 | 63.2 | -0.323 | -68 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -88.7 | -472 | -730 | -1,156 | -769 |
Capital Expenditures | -93.3 | -520 | -976 | -433 | -266 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 45.9 | 0 | — | -595 | 1,018 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -47.4 | -520 | -976 | -1,028 | 752 |
Financing Cash Flow Items | 70.3 | 0 | — | — | -7.95 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 62 | 5,638 | -76.5 | -25.3 | 10.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -77.4 | 4,375 | -1,841 | -2,149 | 32.3 |